Karyopharm's oncology segment is dedicated to the research, development, and commercialization of novel therapies for various cancer types. The company's lead product, XPOVIO (selinexor), plays a central role in this segment, targeting the nuclear export protein XPO1. Research and development efforts focus on expanding the applications of selinexor in different cancer indications, including multiple myeloma, diffuse large B-cell lymphoma, and endometrial cancer. Clinical trials are ongoing to evaluate selinexor as a monotherapy and in combination with other anti-cancer agents. The segment aims to improve patient outcomes by providing innovative treatment options for cancers with high unmet medical needs. Future opportunities include exploring new SINE compounds and personalized medicine approaches.